Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | Director | January 05, 2023 | January 09, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date January 05, 2023 · Filed January 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,226 |
Reported balance
After 2023-01-05 transaction · row 1
1 source rowRow 1 · 2023-01-05 · Grant · Acquired 27,613 · Balance 43,226 F1: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.07 · Expires 2023-01-05 | Direct | 7,080 |
Reported balance
After 2023-01-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-01-05 · Grant · Acquired 7,080 · Balance 7,080 F4: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.31 · Expires 2029-04-29 | Direct | 9,627 |
Reported balance
Holding disclosure · report date 2023-01-05 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 9,627 F2: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.57 · Expires 2029-12-16 | Direct | 5,568 |
Reported balance
Holding disclosure · report date 2023-01-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 5,568 F2: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.06 · Expires 2031-01-06 | Direct | 6,850 |
Reported balance
Holding disclosure · report date 2023-01-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 6,850 F2: Fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.82 · Expires 2031-12-14 | Direct | 7,062 |
Reported balance
Holding disclosure · report date 2023-01-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 7,062 F3: This option vests as to 2,354 shares on each of 12/14/21, 12/14/22 and 12/14/23. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date.
F2: Fully exercisable.
F3: This option vests as to 2,354 shares on each of 12/14/21, 12/14/22 and 12/14/23.
F4: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 05, 2023 Filed Jan 9, 2023 21:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,080 | $0.00 Strike: $1.07 | $0.00 |
DisclosureSEC source: 0001062993-23-000719 · form4.xml · derivative · entry 6 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,080 Underlying: Common Stock · 7,080 shares Expires 2023-01-05 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors for 2022. This option vests as to 2,360 shares on each of 1/5/23, 1/5/24 and 1/5/25. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:31 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 27,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-000719 · form4.xml · nonDerivative · entry 1 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,226 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors for 2022. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 02:17 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 7,062 | $0.00 Strike: $6.82 | $0.00 |
DisclosureSEC source: 0001437749-21-028835 · rdgdoc.xml · derivative · entry 5 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,062 Underlying: Common Stock · 7,062 shares Expires 2031-12-14 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors. This option vests as to 2,354 shares on each of 12/14/21, 12/14/22 and 12/14/23. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 02:17 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 4,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-028835 · rdgdoc.xml · nonDerivative · entry 1 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,613 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| August 18, 2021 Filed Aug 20, 2021 01:04 UTC | NEPHROS INC NEPH · Entity 7279 | PurchaseCommon Stock | 5,000 | $7.64 | $38,200.00 |
DisclosureSEC source: 0000914190-21-000284 · edgar.xml · nonDerivative · entry 1 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,031 Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:32 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 6,850 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0000914190-21-000010 · edgar.xml · derivative · entry 4 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,850 Underlying: Common Stock · 6,850 shares Expires 2031-01-06 F4 · derivative.exercise_date: Represents options granted to the reporting person for his service on the Company's Board of Directors. This option vests as to 2,284 shares on 1/6/21 and as to 2,283 shares on each of 1/6/22 and 1/6/23. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:32 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 3,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000010 · edgar.xml · nonDerivative · entry 1 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,031 F1 · shares: Represents shares of restricted stock granted to the reporting person in lieu of cash fees payable to the reporting person for his service on the Company's Board of Directors. These shares of restricted stock vest 6 months following the grant date. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:12 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 5,568 | $0.00 Strike: $8.57 | $0.00 |
DisclosureSEC source: 0000914190-19-000506 · edgar.xml · derivative · entry 3 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,568 Underlying: Common Stock · 5,568 shares Expires 2029-12-16 F3 · derivative.exercise_date: On December 16, 2019, the Company granted an option to purchase 5,568 shares of common stock of the Company (the "Option") in respect of the service by Mr. Gwydir as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 1,856 shares on each of 12/16/19, 12/16/20 and 12/16/21. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 22:12 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 2,365 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-19-000506 · edgar.xml · nonDerivative · entry 1 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,365 F1 · shares: On December 16, 2019, the Company granted 2,365 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Gwydir in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| April 29, 2019 Filed May 1, 2019 20:43 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (right to buy) · Derivative | 86,641 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0000914190-19-000136 · edgar.xml · derivative · entry 1 Gwydir Tom · CIK 0001775308 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,641 Underlying: Common Stock · 86,641 shares Expires 2029-04-29 F1 · derivative.exercise_date: On April 29, 2019, the Company granted to Mr. Gwydir an option to purchase 86,641shares of common stock of the Company, of which one-third vested immediately upon the grant date, one-third will vest on the first anniversary of the grant date, and the remaining one-third will vest on the second anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.